pacritinib (Vonjo) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).   Wikipedia

Chemistry

  • SMILES: C(CN1CCCC1)Oc2ccc3Nc4nccc(n4)c5cccc(COC\C=C\COCc2c3)c5
  • InChIKey: HWXVIOGONBBTBY-ONEGZZNKSA-N
  • Mol. Mass: 472.59
  • ALogP: 4.96
  • ChEMBL Molecule:
    pacritinib  
More Chemistry

Pharmacology

Alternative names

11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene | onx-0803 | otl38 | pacritinib | sb1518 | sb 1518 | sb-1518

Organizations (42)

Research & Development (42)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (35)

Approved Indications (3)


 

Polycythemia (approved 2022)

Primary Myelofibrosis (approved 2022)

Thrombocythemia, Essential (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (34)


 

Arthritis, Rheumatoid (Phase 1)

Breast Neoplasms (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 2)

COVID-19 (Phase 3)

Drug Interactions (Phase 1)

Graft vs Host Disease (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

Hodgkin Disease (Phase 2)

Inflammatory Bowel Diseases (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1/Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 1)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Lymphoproliferative Disorders (Phase 2)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Pituitary Neoplasms (Phase 1)

Polycythemia Vera (Phase 3)

Primary Myelofibrosis (Phase 3)

Prostatic Neoplasms (Phase 2)

Thrombocythemia, Essential (Phase 1/Phase 2)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 49
  • # of Trial Organizations: 42

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue